IL15 and T-cell large granular lymphocyte leukemia: Initial clinical trials targeting IL-15 had been unsuccessful (81, 82), but recent positive clinical data from a phase 1/2 clinical study (NCT03239392) of BNZ-1, a multi-cytokine inhibitor was presented at the 62nd American Society of Hematology (ASH) Annual Meeting suggests that IL-15 inhibition can induce clinical responses in patients with T-LGLL, particularly those with transfusion dependence (83).